FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110990434> ?p ?o ?g. }

• W2110990434 endingPage "1402" @default.
• W2110990434 startingPage "1391" @default.
• W2110990434 abstract "BACKGROUND Metabolic syndrome (MetS) and benign prostate hyperplasia (BPH)/low urinary tract symptoms (LUTS) are often comorbid. Chronic inflammation is one of the putative links between these diseases. Phosphodiesterase type 5 inhibitors (PDE5i) are recognized as an effective treatment of BPH-related LUTS. One proposed mechanism of action of PDE5 is the inhibition of intraprostatic inflammation. In this study we investigate whether PDE5i could blunt inflammation in the human prostate. METHODS Evaluation of the effect of tadalafil and vardenafil on secretion of interleukin 8 (IL-8, a surrogate marker of prostate inflammation) by human myofibroblast prostatic cells (hBPH) exposed to different inflammatory stimuli. We preliminary evaluate histological features of prostatic inflammatory infiltrates in BPH patients enrolled in a randomized, double bind, placebo controlled study aimed at investigating the efficacy of vardenafil (10 mg/day, for 12 weeks) on BPH/LUTS. RESULTS In vitro treatment with tadalafil or vardenafil on hBPH reduced IL-8 secretion induced by either TNFα or metabolic factors, including oxidized low-density lipoprotein, oxLDL, to the same extent as a PDE5-insensitive PKG agonist Sp-8-Br-PET-cGMP. These effects were reverted by the PKG inhibitor KT5823, suggesting a cGMP/PKG-dependency. Treatment with tadalafil or vardenafil significantly suppressed oxLDL receptor (LOX-1) expression. Histological evaluation of anti-CD45 staining (CD45 score) in prostatectomy specimens of BPH patients showed a positive association with MetS severity. Reduced HDL-cholesterol and elevated triglycerides were the only MetS factors significantly associated with CD45 score. In the MetS cohort there was a significant lower CD45 score in the vardenafil-arm versus the placebo-one. Prostate 73: 1391–1402, 2013. © 2013 Wiley Periodicals, Inc." @default.
• W2110990434 created "2016-06-24" @default.
• W2110990434 creator A5012539089 @default.
• W2110990434 creator A5020071187 @default.
• W2110990434 creator A5020102317 @default.
• W2110990434 creator A5021208002 @default.
• W2110990434 creator A5024248018 @default.
• W2110990434 creator A5042036655 @default.
• W2110990434 creator A5049759930 @default.
• W2110990434 creator A5059786789 @default.
• W2110990434 creator A5072623709 @default.
• W2110990434 creator A5080620058 @default.
• W2110990434 creator A5083521250 @default.
• W2110990434 creator A5087124732 @default.
• W2110990434 creator A5088049956 @default.
• W2110990434 date "2013-06-13" @default.
• W2110990434 modified "2023-09-24" @default.
• W2110990434 title "PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS" @default.
• W2110990434 cites W1491869245 @default.
• W2110990434 cites W1523426257 @default.
• W2110990434 cites W1548257999 @default.
• W2110990434 cites W1962507201 @default.
• W2110990434 cites W1964683861 @default.
• W2110990434 cites W1971272236 @default.
• W2110990434 cites W1991334358 @default.
• W2110990434 cites W1991668544 @default.
• W2110990434 cites W1993506111 @default.
• W2110990434 cites W1994414216 @default.
• W2110990434 cites W1997825003 @default.
• W2110990434 cites W2005251132 @default.
• W2110990434 cites W2018679156 @default.
• W2110990434 cites W2020539470 @default.
• W2110990434 cites W2027367061 @default.
• W2110990434 cites W2040308926 @default.
• W2110990434 cites W2045504344 @default.
• W2110990434 cites W2054586831 @default.
• W2110990434 cites W2064819768 @default.
• W2110990434 cites W2065022828 @default.
• W2110990434 cites W2069489942 @default.
• W2110990434 cites W2075608594 @default.
• W2110990434 cites W2081092531 @default.
• W2110990434 cites W2082384828 @default.
• W2110990434 cites W2086685901 @default.
• W2110990434 cites W2088517597 @default.
• W2110990434 cites W2088986244 @default.
• W2110990434 cites W2089521599 @default.
• W2110990434 cites W2090700025 @default.
• W2110990434 cites W2093683062 @default.
• W2110990434 cites W2097752676 @default.
• W2110990434 cites W2106039105 @default.
• W2110990434 cites W2113257598 @default.
• W2110990434 cites W2114542908 @default.
• W2110990434 cites W2115667294 @default.
• W2110990434 cites W2120429719 @default.
• W2110990434 cites W2124143789 @default.
• W2110990434 cites W2124892033 @default.
• W2110990434 cites W2131627141 @default.
• W2110990434 cites W2134725999 @default.
• W2110990434 cites W2136366313 @default.
• W2110990434 cites W2139438378 @default.
• W2110990434 cites W2141932304 @default.
• W2110990434 cites W2145584597 @default.
• W2110990434 cites W2148516205 @default.
• W2110990434 cites W2156445049 @default.
• W2110990434 cites W2164113696 @default.
• W2110990434 cites W2168839555 @default.
• W2110990434 cites W2172207849 @default.
• W2110990434 cites W2807400090 @default.
• W2110990434 cites W2953200146 @default.
• W2110990434 doi "https://doi.org/10.1002/pros.22686" @default.
• W2110990434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23765639" @default.
• W2110990434 hasPublicationYear "2013" @default.
• W2110990434 type Work @default.
• W2110990434 sameAs 2110990434 @default.
• W2110990434 citedByCount "99" @default.
• W2110990434 countsByYear W21109904342014 @default.
• W2110990434 countsByYear W21109904342015 @default.
• W2110990434 countsByYear W21109904342016 @default.
• W2110990434 countsByYear W21109904342017 @default.
• W2110990434 countsByYear W21109904342018 @default.
• W2110990434 countsByYear W21109904342019 @default.
• W2110990434 countsByYear W21109904342020 @default.
• W2110990434 countsByYear W21109904342021 @default.
• W2110990434 countsByYear W21109904342022 @default.
• W2110990434 countsByYear W21109904342023 @default.
• W2110990434 crossrefType "journal-article" @default.
• W2110990434 hasAuthorship W2110990434A5012539089 @default.
• W2110990434 hasAuthorship W2110990434A5020071187 @default.
• W2110990434 hasAuthorship W2110990434A5020102317 @default.
• W2110990434 hasAuthorship W2110990434A5021208002 @default.
• W2110990434 hasAuthorship W2110990434A5024248018 @default.
• W2110990434 hasAuthorship W2110990434A5042036655 @default.
• W2110990434 hasAuthorship W2110990434A5049759930 @default.
• W2110990434 hasAuthorship W2110990434A5059786789 @default.
• W2110990434 hasAuthorship W2110990434A5072623709 @default.
• W2110990434 hasAuthorship W2110990434A5080620058 @default.
• W2110990434 hasAuthorship W2110990434A5083521250 @default.
• W2110990434 hasAuthorship W2110990434A5087124732 @default.

• next